Intrathecal pemetrexed chemotherapy combined with systemic therapy in patients with non-small cell lung cancer and leptomeningeal metastases: a retrospective study
BackgroundLeptomeningeal metastases (LM) in non-small cell lung cancer (NSCLC) present a challenging prognosis, with systemic therapies often limited by the blood-brain barrier. However, intrathecal pemetrexed injections can increase intracranial drug concentrations, aiding in disease control.Object...
Saved in:
| Main Authors: | Wenjuan Zhong, Longqiu Wu, Zhengang Qiu, Wei Yu, Linfang Liu, Huaqiu Shi, Shugui Wu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1545174/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy
by: Shugui Wu, et al.
Published: (2025-05-01) -
Intrathecal administration of PD-1 inhibitor combined with pemetrexed for leptomeningeal metastases from breast cancer: a case report
by: Yushan Huang, et al.
Published: (2025-04-01) -
HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
by: Scott A Wu, et al.
Published: (2023-09-01) -
Intrathecal pemetrexed efficacy and cerebrospinal fluid tumor marker response in refractory leptomeningeal metastasis of non-small-cell lung cancer: a single-arm phase II trial
by: Qingsheng Xu, et al.
Published: (2025-05-01) -
Intrathecal Trastuzumab as a Novel Simplified Therapeutic Strategy for Isolated Metastases in the Leptomeninges in HER2-Positive Breast Cancer: A Case Report and Review of Literature
by: Lokesh K. Nagendrappa, et al.